Equivalent results were obtained in Ldlr−/− mice with advanced atherosclerosis, which were treated with the agonist Ac2-26 packed into nanoparticles that targeted type IV collagen to ensure deposition in atherosclerotic lesions. This evidence concerns the gene LDLR and atherosclerosis.